These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 8442843)
1. Health authorities and drug utilization studies. Garcia Alonso F; Scott AI; Stika L; Westerholm B WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843 [No Abstract] [Full Text] [Related]
2. Drug utilization studies within the VIDEOFAR project. Maggini M; Menniti Ippolito F; Spila Alegiani S; Traversa G; Fortini M Ann Ist Super Sanita; 1991; 27(2):201-6. PubMed ID: 1755571 [TBL] [Abstract][Full Text] [Related]
3. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States. Strom BL Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576 [TBL] [Abstract][Full Text] [Related]
4. Drug utilization and the health professions. Kimbel KH WHO Reg Publ Eur Ser; 1993; 45():169-76. PubMed ID: 8442844 [No Abstract] [Full Text] [Related]
5. Information systems for the analysis of drug prescriptions in Spain. Ferrando MC Ann Ist Super Sanita; 1991; 27(2):213-6. PubMed ID: 1755573 [TBL] [Abstract][Full Text] [Related]
6. VIDEOFAR: an epidemiologic tool for drug utilization studies. Raschetti R Ann Ist Super Sanita; 1991; 27(2):191-3. PubMed ID: 1755569 [TBL] [Abstract][Full Text] [Related]
7. Drug utilization studies and drug monitoring in The Netherlands. Haaijer-Ruskamp FM; de Jong-van den Berg LT Ann Ist Super Sanita; 1991; 27(2):217-23. PubMed ID: 1755574 [TBL] [Abstract][Full Text] [Related]
8. Drug utilization studies and people. A Swedish perspective. Tomson G Ann Ist Super Sanita; 1991; 27(2):239-45. PubMed ID: 1755577 [TBL] [Abstract][Full Text] [Related]
9. The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist. O'Malley P Clin Nurse Spec; 2007; 21(4):188-90. PubMed ID: 17622806 [No Abstract] [Full Text] [Related]
10. The quantification of drug risks in practice. Lee D; Bergman U WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852 [No Abstract] [Full Text] [Related]
11. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
12. [Pharmacology at the start of a new millennium. Larger assortment and individual drug dosing are coming]. Fredholm BB; Sjöqvist F Lakartidningen; 2001 Feb; 98(6):534-9. PubMed ID: 11475239 [No Abstract] [Full Text] [Related]
13. Trends in opioid consumption in the Nordic countries 2002-2006. Hamunen K; Paakkari P; Kalso E Eur J Pain; 2009 Oct; 13(9):954-62. PubMed ID: 19091608 [TBL] [Abstract][Full Text] [Related]
14. Drug recalls and notification of practitioners. Rodts MF Orthop Nurs; 2004; 23(6):353-4. PubMed ID: 15682877 [No Abstract] [Full Text] [Related]
17. Overview of different logistical approaches to postmarketing surveillance. Strom BL J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621 [TBL] [Abstract][Full Text] [Related]
18. Drug policy: the challenge is to overcome fragmentation. McFarlance A Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109 [TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions and reporting. Witte R Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100 [No Abstract] [Full Text] [Related]
20. [Drug utilization should be analyzed on the premises]. Hoffmann M; Ahlner J Lakartidningen; 1995 Oct; 92(41):3808-10. PubMed ID: 7564635 [No Abstract] [Full Text] [Related] [Next] [New Search]